#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Default mode network connectivity is associated with long-term clinical outcome in patients with schizophrenia This study investigated whether resting-state functional connectivity is associated with long-term clinical outcomes of patients with schizophrenia.
1-1	0-7	Default	_
1-2	8-12	mode	_
1-3	13-20	network	_
1-4	21-33	connectivity	_
1-5	34-36	is	_
1-6	37-47	associated	_
1-7	48-52	with	_
1-8	53-62	long-term	_
1-9	63-71	clinical	_
1-10	72-79	outcome	_
1-11	80-82	in	_
1-12	83-91	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-13	92-96	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-14	97-110	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-15	111-115	This	_
1-16	116-121	study	_
1-17	122-134	investigated	_
1-18	135-142	whether	_
1-19	143-156	resting-state	_
1-20	157-167	functional	_
1-21	168-180	connectivity	_
1-22	181-183	is	_
1-23	184-194	associated	_
1-24	195-199	with	_
1-25	200-209	long-term	_
1-26	210-218	clinical	_
1-27	219-227	outcomes	_
1-28	228-230	of	_
1-29	231-239	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-30	240-244	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-31	245-258	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-32	259-260	.	_

Text=Resting-state brain images were obtained from 79 outpatients with schizophrenia and 30 healthy controls (HC), using a 3 T-MRI scanner.
2-1	261-274	Resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
2-2	275-280	brain	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
2-3	281-287	images	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
2-4	288-292	were	_
2-5	293-301	obtained	_
2-6	302-306	from	_
2-7	307-309	79	_
2-8	310-321	outpatients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-9	322-326	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-10	327-340	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-11	341-344	and	_
2-12	345-347	30	_
2-13	348-355	healthy	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
2-14	356-364	controls	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
2-15	365-366	(	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
2-16	367-369	HC	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
2-17	370-371	)	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
2-18	372-373	,	_
2-19	374-379	using	_
2-20	380-381	a	_
2-21	382-383	3	_
2-22	384-389	T-MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
2-23	390-397	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
2-24	398-399	.	_

Text=All patients were 20–50 years old with> 3 years' duration of illness and appeared clinically stable.
3-1	400-403	All	_
3-2	404-412	patients	_
3-3	413-417	were	_
3-4	418-423	20–50	_
3-5	424-429	years	_
3-6	430-433	old	_
3-7	434-438	with	_
3-8	439-440	>	_
3-9	441-442	3	_
3-10	443-448	years	_
3-11	449-450	'	_
3-12	451-459	duration	_
3-13	460-462	of	_
3-14	463-470	illness	_
3-15	471-474	and	_
3-16	475-483	appeared	_
3-17	484-494	clinically	_
3-18	495-501	stable	_
3-19	502-503	.	_

Text=We assessed their psychopathology using the 18-item Brief Psychiatric Rating Scale (BPRS-18) and divided them into “ good, ” “ moderate, ” and “ poor ” outcome (SZ-GO, SZ-MO, and SZ-PO) groups depending on BPRS-18 total score.
4-1	504-506	We	_
4-2	507-515	assessed	_
4-3	516-521	their	_
4-4	522-537	psychopathology	_
4-5	538-543	using	_
4-6	544-547	the	_
4-7	548-555	18-item	_
4-8	556-561	Brief	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
4-9	562-573	Psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
4-10	574-580	Rating	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
4-11	581-586	Scale	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
4-12	587-588	(	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
4-13	589-596	BPRS-18	http://maven.renci.org/NeuroBridge/neurobridge#Thing
4-14	597-598	)	http://maven.renci.org/NeuroBridge/neurobridge#Thing
4-15	599-602	and	_
4-16	603-610	divided	_
4-17	611-615	them	_
4-18	616-620	into	_
4-19	621-622	“	_
4-20	623-627	good	_
4-21	628-629	,	_
4-22	630-631	”	_
4-23	632-633	“	_
4-24	634-642	moderate	_
4-25	643-644	,	_
4-26	645-646	”	_
4-27	647-650	and	_
4-28	651-652	“	_
4-29	653-657	poor	_
4-30	658-659	”	_
4-31	660-667	outcome	_
4-32	668-669	(	_
4-33	670-675	SZ-GO	_
4-34	676-677	,	_
4-35	678-683	SZ-MO	_
4-36	684-685	,	_
4-37	686-689	and	_
4-38	690-695	SZ-PO	_
4-39	696-697	)	_
4-40	698-704	groups	_
4-41	705-714	depending	_
4-42	715-717	on	_
4-43	718-725	BPRS-18	_
4-44	726-731	total	_
4-45	732-737	score	_
4-46	738-739	.	_

Text=We obtained individual functional connectivity maps between a seed region of the bilateral posterior cingulate cortex (PCC) and all other brain regions and compared the functional connectivity of the default mode network (DMN) among the HC and 3 schizophrenia outcome groups, with a voxel-wise threshold of P <.001 within a cluster-extent threshold of 114 voxels.
5-1	740-742	We	_
5-2	743-751	obtained	_
5-3	752-762	individual	_
5-4	763-773	functional	_
5-5	774-786	connectivity	_
5-6	787-791	maps	_
5-7	792-799	between	_
5-8	800-801	a	_
5-9	802-806	seed	_
5-10	807-813	region	_
5-11	814-816	of	_
5-12	817-820	the	_
5-13	821-830	bilateral	_
5-14	831-840	posterior	_
5-15	841-850	cingulate	_
5-16	851-857	cortex	_
5-17	858-859	(	_
5-18	860-863	PCC	_
5-19	864-865	)	_
5-20	866-869	and	_
5-21	870-873	all	_
5-22	874-879	other	_
5-23	880-885	brain	_
5-24	886-893	regions	_
5-25	894-897	and	_
5-26	898-906	compared	_
5-27	907-910	the	_
5-28	911-921	functional	_
5-29	922-934	connectivity	_
5-30	935-937	of	_
5-31	938-941	the	_
5-32	942-949	default	_
5-33	950-954	mode	_
5-34	955-962	network	_
5-35	963-964	(	_
5-36	965-968	DMN	_
5-37	969-970	)	_
5-38	971-976	among	_
5-39	977-980	the	_
5-40	981-983	HC	_
5-41	984-987	and	_
5-42	988-989	3	_
5-43	990-1003	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-44	1004-1011	outcome	_
5-45	1012-1018	groups	_
5-46	1019-1020	,	_
5-47	1021-1025	with	_
5-48	1026-1027	a	_
5-49	1028-1038	voxel-wise	_
5-50	1039-1048	threshold	_
5-51	1049-1051	of	_
5-52	1052-1053	P	_
5-53	1054-1055	<	_
5-54	1056-1060	.001	_
5-55	1061-1067	within	_
5-56	1068-1069	a	_
5-57	1070-1084	cluster-extent	_
5-58	1085-1094	threshold	_
5-59	1095-1097	of	_
5-60	1098-1101	114	_
5-61	1102-1108	voxels	_
5-62	1109-1110	.	_

Text=Additionally, we assessed correlations between functional connectivity and BPRS-18 scores.
6-1	1111-1123	Additionally	_
6-2	1124-1125	,	_
6-3	1126-1128	we	_
6-4	1129-1137	assessed	_
6-5	1138-1150	correlations	_
6-6	1151-1158	between	_
6-7	1159-1169	functional	_
6-8	1170-1182	connectivity	_
6-9	1183-1186	and	_
6-10	1187-1194	BPRS-18	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
6-11	1195-1201	scores	_
6-12	1202-1203	.	_

Text=The SZ-MO and SZ-PO groups showed decreased functional connectivity between PCC and right ventromedial prefrontal cortex (vmPFC), left middle cingulate cortex, and left frontopolar cortex (FPC) compared to the SZ-GO and HC groups.
7-1	1204-1207	The	_
7-2	1208-1213	SZ-MO	http://maven.renci.org/NeuroBridge/neurobridge#Thing
7-3	1214-1217	and	_
7-4	1218-1223	SZ-PO	http://maven.renci.org/NeuroBridge/neurobridge#Thing
7-5	1224-1230	groups	_
7-6	1231-1237	showed	_
7-7	1238-1247	decreased	_
7-8	1248-1258	functional	_
7-9	1259-1271	connectivity	_
7-10	1272-1279	between	_
7-11	1280-1283	PCC	_
7-12	1284-1287	and	_
7-13	1288-1293	right	_
7-14	1294-1306	ventromedial	_
7-15	1307-1317	prefrontal	_
7-16	1318-1324	cortex	_
7-17	1325-1326	(	_
7-18	1327-1332	vmPFC	_
7-19	1333-1334	)	_
7-20	1335-1336	,	_
7-21	1337-1341	left	_
7-22	1342-1348	middle	_
7-23	1349-1358	cingulate	_
7-24	1359-1365	cortex	_
7-25	1366-1367	,	_
7-26	1368-1371	and	_
7-27	1372-1376	left	_
7-28	1377-1388	frontopolar	_
7-29	1389-1395	cortex	_
7-30	1396-1397	(	_
7-31	1398-1401	FPC	_
7-32	1402-1403	)	_
7-33	1404-1412	compared	_
7-34	1413-1415	to	_
7-35	1416-1419	the	_
7-36	1420-1425	SZ-GO	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask
7-37	1426-1429	and	_
7-38	1430-1432	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
7-39	1433-1439	groups	_
7-40	1440-1441	.	_

Text=DMN connectivity in the right vmPFC and left FPC negatively correlated with subscale scores of the BPRS-18, except the negative symptoms subscale.
8-1	1442-1445	DMN	_
8-2	1446-1458	connectivity	_
8-3	1459-1461	in	_
8-4	1462-1465	the	_
8-5	1466-1471	right	_
8-6	1472-1477	vmPFC	_
8-7	1478-1481	and	_
8-8	1482-1486	left	_
8-9	1487-1490	FPC	_
8-10	1491-1501	negatively	_
8-11	1502-1512	correlated	_
8-12	1513-1517	with	_
8-13	1518-1526	subscale	_
8-14	1527-1533	scores	_
8-15	1534-1536	of	_
8-16	1537-1540	the	_
8-17	1541-1548	BPRS-18	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
8-18	1549-1550	,	_
8-19	1551-1557	except	_
8-20	1558-1561	the	_
8-21	1562-1570	negative	_
8-22	1571-1579	symptoms	_
8-23	1580-1588	subscale	_
8-24	1589-1590	.	_

Text=In this study, poorer clinical outcomes in patients with schizophrenia were associated with decreased DMN connectivity.
9-1	1591-1593	In	_
9-2	1594-1598	this	_
9-3	1599-1604	study	_
9-4	1605-1606	,	_
9-5	1607-1613	poorer	_
9-6	1614-1622	clinical	_
9-7	1623-1631	outcomes	_
9-8	1632-1634	in	_
9-9	1635-1643	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-10	1644-1648	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-11	1649-1662	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-12	1663-1667	were	_
9-13	1668-1678	associated	_
9-14	1679-1683	with	_
9-15	1684-1693	decreased	_
9-16	1694-1697	DMN	_
9-17	1698-1710	connectivity	_
9-18	1711-1712	.	_

Text=In particular, the decreased functional connectivity might be related to the severity of positive and mood symptoms rather than negative symptoms.
10-1	1713-1715	In	_
10-2	1716-1726	particular	_
10-3	1727-1728	,	_
10-4	1729-1732	the	_
10-5	1733-1742	decreased	_
10-6	1743-1753	functional	_
10-7	1754-1766	connectivity	_
10-8	1767-1772	might	_
10-9	1773-1775	be	_
10-10	1776-1783	related	_
10-11	1784-1786	to	_
10-12	1787-1790	the	_
10-13	1791-1799	severity	_
10-14	1800-1802	of	_
10-15	1803-1811	positive	_
10-16	1812-1815	and	_
10-17	1816-1820	mood	_
10-18	1821-1829	symptoms	_
10-19	1830-1836	rather	_
10-20	1837-1841	than	_
10-21	1842-1850	negative	_
10-22	1851-1859	symptoms	_
10-23	1860-1861	.	_

Text=Highlights Long-term outcome of schizophrenia is related to default mode network connectivity.
11-1	1862-1872	Highlights	_
11-2	1873-1882	Long-term	_
11-3	1883-1890	outcome	_
11-4	1891-1893	of	_
11-5	1894-1907	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
11-6	1908-1910	is	_
11-7	1911-1918	related	_
11-8	1919-1921	to	_
11-9	1922-1929	default	_
11-10	1930-1934	mode	_
11-11	1935-1942	network	_
11-12	1943-1955	connectivity	_
11-13	1956-1957	.	_

Text=Decreased functional connectivity is associated with poorer clinical outcome.
12-1	1958-1967	Decreased	_
12-2	1968-1978	functional	_
12-3	1979-1991	connectivity	_
12-4	1992-1994	is	_
12-5	1995-2005	associated	_
12-6	2006-2010	with	_
12-7	2011-2017	poorer	_
12-8	2018-2026	clinical	_
12-9	2027-2034	outcome	_
12-10	2035-2036	.	_

Text=Functional connectivity negatively correlates with positive and mood symptoms.
13-1	2037-2047	Functional	_
13-2	2048-2060	connectivity	_
13-3	2061-2071	negatively	_
13-4	2072-2082	correlates	_
13-5	2083-2087	with	_
13-6	2088-2096	positive	_
13-7	2097-2100	and	_
13-8	2101-2105	mood	_
13-9	2106-2114	symptoms	_
13-10	2115-2116	.	_

Text=Materials and methods Subjects All subjects were interviewed by a psychologist (K.P.
14-1	2117-2126	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
14-2	2127-2130	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
14-3	2131-2138	methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
14-4	2139-2147	Subjects	_
14-5	2148-2151	All	_
14-6	2152-2160	subjects	_
14-7	2161-2165	were	_
14-8	2166-2177	interviewed	_
14-9	2178-2180	by	_
14-10	2181-2182	a	_
14-11	2183-2195	psychologist	_
14-12	2196-2197	(	_
14-13	2198-2201	K.P	_
14-14	2202-2203	.	_

Text=), who used the Mini-International Neuropsychiatric Interview (MINI) to make diagnoses of psychiatric disorders according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV).
15-1	2204-2205	)	_
15-2	2206-2207	,	_
15-3	2208-2211	who	_
15-4	2212-2216	used	_
15-5	2217-2220	the	_
15-6	2221-2239	Mini-International	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
15-7	2240-2256	Neuropsychiatric	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
15-8	2257-2266	Interview	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
15-9	2267-2268	(	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
15-10	2269-2273	MINI	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
15-11	2274-2275	)	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
15-12	2276-2278	to	_
15-13	2279-2283	make	_
15-14	2284-2293	diagnoses	_
15-15	2294-2296	of	_
15-16	2297-2308	psychiatric	_
15-17	2309-2318	disorders	_
15-18	2319-2328	according	_
15-19	2329-2331	to	_
15-20	2332-2335	the	_
15-21	2336-2346	Diagnostic	_
15-22	2347-2350	and	_
15-23	2351-2362	Statistical	_
15-24	2363-2369	Manual	_
15-25	2370-2372	of	_
15-26	2373-2379	Mental	_
15-27	2380-2389	Disorders	_
15-28	2390-2391	,	_
15-29	2392-2398	Fourth	_
15-30	2399-2406	Edition	_
15-31	2407-2408	(	_
15-32	2409-2415	DSM-IV	_
15-33	2416-2417	)	_
15-34	2418-2419	.	_

Text=Patients who met the DSM-IV criteria for schizophrenia were recruited from outpatient clinics of the National Center for Mental Health, Seoul, Republic of Korea.
16-1	2420-2428	Patients	_
16-2	2429-2432	who	_
16-3	2433-2436	met	_
16-4	2437-2440	the	_
16-5	2441-2447	DSM-IV	_
16-6	2448-2456	criteria	_
16-7	2457-2460	for	_
16-8	2461-2474	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
16-9	2475-2479	were	_
16-10	2480-2489	recruited	_
16-11	2490-2494	from	_
16-12	2495-2505	outpatient	_
16-13	2506-2513	clinics	_
16-14	2514-2516	of	_
16-15	2517-2520	the	_
16-16	2521-2529	National	_
16-17	2530-2536	Center	_
16-18	2537-2540	for	_
16-19	2541-2547	Mental	_
16-20	2548-2554	Health	_
16-21	2555-2556	,	_
16-22	2557-2562	Seoul	_
16-23	2563-2564	,	_
16-24	2565-2573	Republic	_
16-25	2574-2576	of	_
16-26	2577-2582	Korea	_
16-27	2583-2584	.	_

Text=Inclusion criteria were as follows: (1) aged 20–50 years; (2) duration of illness> 3 years; (3) appeared clinically stable, as defined by no exacerbation of psychotic symptoms and no change in general clinical state and medication for at least 3 months prior to the time of assessment.
17-1	2585-2594	Inclusion	_
17-2	2595-2603	criteria	_
17-3	2604-2608	were	_
17-4	2609-2611	as	_
17-5	2612-2619	follows	_
17-6	2620-2621	:	_
17-7	2622-2623	(	_
17-8	2624-2625	1	_
17-9	2626-2627	)	_
17-10	2628-2632	aged	_
17-11	2633-2638	20–50	_
17-12	2639-2644	years	_
17-13	2645-2646	;	_
17-14	2647-2648	(	_
17-15	2649-2650	2	_
17-16	2651-2652	)	_
17-17	2653-2661	duration	_
17-18	2662-2664	of	_
17-19	2665-2672	illness	_
17-20	2673-2674	>	_
17-21	2675-2676	3	_
17-22	2677-2682	years	_
17-23	2683-2684	;	_
17-24	2685-2686	(	_
17-25	2687-2688	3	_
17-26	2689-2690	)	_
17-27	2691-2699	appeared	_
17-28	2700-2710	clinically	_
17-29	2711-2717	stable	_
17-30	2718-2719	,	_
17-31	2720-2722	as	_
17-32	2723-2730	defined	_
17-33	2731-2733	by	_
17-34	2734-2736	no	_
17-35	2737-2749	exacerbation	_
17-36	2750-2752	of	_
17-37	2753-2762	psychotic	_
17-38	2763-2771	symptoms	_
17-39	2772-2775	and	_
17-40	2776-2778	no	_
17-41	2779-2785	change	_
17-42	2786-2788	in	_
17-43	2789-2796	general	_
17-44	2797-2805	clinical	_
17-45	2806-2811	state	_
17-46	2812-2815	and	_
17-47	2816-2826	medication	_
17-48	2827-2830	for	_
17-49	2831-2833	at	_
17-50	2834-2839	least	_
17-51	2840-2841	3	_
17-52	2842-2848	months	_
17-53	2849-2854	prior	_
17-54	2855-2857	to	_
17-55	2858-2861	the	_
17-56	2862-2866	time	_
17-57	2867-2869	of	_
17-58	2870-2880	assessment	_
17-59	2881-2882	.	_

Text=We excluded patients with a concurrent axis I diagnosis according to the DSM-IV, current or past neurological disease, any contraindication to MRI scan, or a physical condition that would render an MRI scan difficult to administer or interpret, e.g., severe extrapyramidal symptoms.
18-1	2883-2885	We	_
18-2	2886-2894	excluded	_
18-3	2895-2903	patients	_
18-4	2904-2908	with	_
18-5	2909-2910	a	_
18-6	2911-2921	concurrent	_
18-7	2922-2926	axis	_
18-8	2927-2928	I	_
18-9	2929-2938	diagnosis	_
18-10	2939-2948	according	_
18-11	2949-2951	to	_
18-12	2952-2955	the	_
18-13	2956-2962	DSM-IV	_
18-14	2963-2964	,	_
18-15	2965-2972	current	_
18-16	2973-2975	or	_
18-17	2976-2980	past	_
18-18	2981-2993	neurological	_
18-19	2994-3001	disease	_
18-20	3002-3003	,	_
18-21	3004-3007	any	_
18-22	3008-3024	contraindication	_
18-23	3025-3027	to	_
18-24	3028-3031	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
18-25	3032-3036	scan	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
18-26	3037-3038	,	_
18-27	3039-3041	or	_
18-28	3042-3043	a	_
18-29	3044-3052	physical	_
18-30	3053-3062	condition	_
18-31	3063-3067	that	_
18-32	3068-3073	would	_
18-33	3074-3080	render	_
18-34	3081-3083	an	_
18-35	3084-3087	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
18-36	3088-3092	scan	_
18-37	3093-3102	difficult	_
18-38	3103-3105	to	_
18-39	3106-3116	administer	_
18-40	3117-3119	or	_
18-41	3120-3129	interpret	_
18-42	3130-3131	,	_
18-43	3132-3136	e.g.	_
18-44	3137-3138	,	_
18-45	3139-3145	severe	_
18-46	3146-3160	extrapyramidal	_
18-47	3161-3169	symptoms	_
18-48	3170-3171	.	_

Text=The HCs consisted of volunteers from the local community who were free of any history of psychiatric disorders.
19-1	3172-3175	The	_
19-2	3176-3179	HCs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
19-3	3180-3189	consisted	_
19-4	3190-3192	of	_
19-5	3193-3203	volunteers	_
19-6	3204-3208	from	_
19-7	3209-3212	the	_
19-8	3213-3218	local	_
19-9	3219-3228	community	_
19-10	3229-3232	who	_
19-11	3233-3237	were	_
19-12	3238-3242	free	_
19-13	3243-3245	of	_
19-14	3246-3249	any	_
19-15	3250-3257	history	_
19-16	3258-3260	of	_
19-17	3261-3272	psychiatric	_
19-18	3273-3282	disorders	_
19-19	3283-3284	.	_

Text=The same exclusion criteria that were applied to the patients also applied to the HC group with regard to medical, neurological, and physical conditions.
20-1	3285-3288	The	_
20-2	3289-3293	same	_
20-3	3294-3303	exclusion	_
20-4	3304-3312	criteria	_
20-5	3313-3317	that	_
20-6	3318-3322	were	_
20-7	3323-3330	applied	_
20-8	3331-3333	to	_
20-9	3334-3337	the	_
20-10	3338-3346	patients	_
20-11	3347-3351	also	_
20-12	3352-3359	applied	_
20-13	3360-3362	to	_
20-14	3363-3366	the	_
20-15	3367-3369	HC	_
20-16	3370-3375	group	_
20-17	3376-3380	with	_
20-18	3381-3387	regard	_
20-19	3388-3390	to	_
20-20	3391-3398	medical	_
20-21	3399-3400	,	_
20-22	3401-3413	neurological	_
20-23	3414-3415	,	_
20-24	3416-3419	and	_
20-25	3420-3428	physical	_
20-26	3429-3439	conditions	_
20-27	3440-3441	.	_

Text=Data from 79 patients and 30 HCs were included in the final analysis.
21-1	3442-3446	Data	_
21-2	3447-3451	from	_
21-3	3452-3454	79	_
21-4	3455-3463	patients	_
21-5	3464-3467	and	_
21-6	3468-3470	30	_
21-7	3471-3474	HCs	_
21-8	3475-3479	were	_
21-9	3480-3488	included	_
21-10	3489-3491	in	_
21-11	3492-3495	the	_
21-12	3496-3501	final	_
21-13	3502-3510	analysis	_
21-14	3511-3512	.	_

Text=This study was initiated after approval of the Institutional Review Board of the National Center for Mental Health (IRB approval number: 116271–2017-26), and written informed consent was obtained from all subjects.
22-1	3513-3517	This	_
22-2	3518-3523	study	_
22-3	3524-3527	was	_
22-4	3528-3537	initiated	_
22-5	3538-3543	after	_
22-6	3544-3552	approval	_
22-7	3553-3555	of	_
22-8	3556-3559	the	_
22-9	3560-3573	Institutional	_
22-10	3574-3580	Review	_
22-11	3581-3586	Board	_
22-12	3587-3589	of	_
22-13	3590-3593	the	_
22-14	3594-3602	National	_
22-15	3603-3609	Center	_
22-16	3610-3613	for	_
22-17	3614-3620	Mental	_
22-18	3621-3627	Health	_
22-19	3628-3629	(	_
22-20	3630-3633	IRB	_
22-21	3634-3642	approval	_
22-22	3643-3649	number	_
22-23	3650-3651	:	_
22-24	3652-3666	116271–2017-26	_
22-25	3667-3668	)	_
22-26	3669-3670	,	_
22-27	3671-3674	and	_
22-28	3675-3682	written	_
22-29	3683-3691	informed	_
22-30	3692-3699	consent	_
22-31	3700-3703	was	_
22-32	3704-3712	obtained	_
22-33	3713-3717	from	_
22-34	3718-3721	all	_
22-35	3722-3730	subjects	_
22-36	3731-3732	.	_

Text=Clinical assessments and group assignment We defined long-term outcome of schizophrenia as overall severity of residual psychopathology in clinically stable patients with chronic schizophrenia whose clinical progression was considered to have reached a plateau after 3 years of onset.
23-1	3733-3741	Clinical	_
23-2	3742-3753	assessments	_
23-3	3754-3757	and	_
23-4	3758-3763	group	_
23-5	3764-3774	assignment	_
23-6	3775-3777	We	_
23-7	3778-3785	defined	_
23-8	3786-3795	long-term	_
23-9	3796-3803	outcome	_
23-10	3804-3806	of	_
23-11	3807-3820	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
23-12	3821-3823	as	_
23-13	3824-3831	overall	_
23-14	3832-3840	severity	_
23-15	3841-3843	of	_
23-16	3844-3852	residual	_
23-17	3853-3868	psychopathology	_
23-18	3869-3871	in	_
23-19	3872-3882	clinically	_
23-20	3883-3889	stable	_
23-21	3890-3898	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
23-22	3899-3903	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
23-23	3904-3911	chronic	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
23-24	3912-3925	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
23-25	3926-3931	whose	_
23-26	3932-3940	clinical	_
23-27	3941-3952	progression	_
23-28	3953-3956	was	_
23-29	3957-3967	considered	_
23-30	3968-3970	to	_
23-31	3971-3975	have	_
23-32	3976-3983	reached	_
23-33	3984-3985	a	_
23-34	3986-3993	plateau	_
23-35	3994-3999	after	_
23-36	4000-4001	3	_
23-37	4002-4007	years	_
23-38	4008-4010	of	_
23-39	4011-4016	onset	_
23-40	4017-4018	.	_

Text=The overall level of the patient's psychopathology was evaluated by a psychiatrist (S.R.
24-1	4019-4022	The	_
24-2	4023-4030	overall	_
24-3	4031-4036	level	_
24-4	4037-4039	of	_
24-5	4040-4043	the	_
24-6	4044-4051	patient	_
24-7	4052-4054	's	_
24-8	4055-4070	psychopathology	_
24-9	4071-4074	was	_
24-10	4075-4084	evaluated	_
24-11	4085-4087	by	_
24-12	4088-4089	a	_
24-13	4090-4102	psychiatrist	_
24-14	4103-4104	(	_
24-15	4105-4108	S.R	_
24-16	4109-4110	.	_

Text=), who used the 18-item Brief Psychiatric Rating Scale (BPRS-18).
25-1	4111-4112	)	_
25-2	4113-4114	,	_
25-3	4115-4118	who	_
25-4	4119-4123	used	_
25-5	4124-4127	the	_
25-6	4128-4135	18-item	_
25-7	4136-4141	Brief	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
25-8	4142-4153	Psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
25-9	4154-4160	Rating	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
25-10	4161-4166	Scale	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
25-11	4167-4168	(	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
25-12	4169-4176	BPRS-18	http://maven.renci.org/NeuroBridge/neurobridge#Thing
25-13	4177-4178	)	http://maven.renci.org/NeuroBridge/neurobridge#Thing
25-14	4179-4180	.	_

Text=proposed that “ mildly ill ” according to the Clinical Global Impression (CGI) scale corresponds to BPRS-18 total scores of 18–31 and “ moderately ill ” corresponds to BPRS-18 total scores of 32–41.
26-1	4181-4189	proposed	_
26-2	4190-4194	that	_
26-3	4195-4196	“	_
26-4	4197-4203	mildly	_
26-5	4204-4207	ill	_
26-6	4208-4209	”	_
26-7	4210-4219	according	_
26-8	4220-4222	to	_
26-9	4223-4226	the	_
26-10	4227-4235	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#ClinicalGlobalImpressionsScale
26-11	4236-4242	Global	http://maven.renci.org/NeuroBridge/neurobridge#ClinicalGlobalImpressionsScale
26-12	4243-4253	Impression	http://maven.renci.org/NeuroBridge/neurobridge#ClinicalGlobalImpressionsScale
26-13	4254-4255	(	http://maven.renci.org/NeuroBridge/neurobridge#ClinicalGlobalImpressionsScale
26-14	4256-4259	CGI	http://maven.renci.org/NeuroBridge/neurobridge#ClinicalGlobalImpressionsScale
26-15	4260-4261	)	http://maven.renci.org/NeuroBridge/neurobridge#ClinicalGlobalImpressionsScale
26-16	4262-4267	scale	_
26-17	4268-4279	corresponds	_
26-18	4280-4282	to	_
26-19	4283-4290	BPRS-18	_
26-20	4291-4296	total	_
26-21	4297-4303	scores	_
26-22	4304-4306	of	_
26-23	4307-4312	18–31	_
26-24	4313-4316	and	_
26-25	4317-4318	“	_
26-26	4319-4329	moderately	_
26-27	4330-4333	ill	_
26-28	4334-4335	”	_
26-29	4336-4347	corresponds	_
26-30	4348-4350	to	_
26-31	4351-4358	BPRS-18	_
26-32	4359-4364	total	_
26-33	4365-4371	scores	_
26-34	4372-4374	of	_
26-35	4375-4380	32–41	_
26-36	4381-4382	.	_

Text=Based on these criteria, we classified the patients into 3 groups: SZ-GO (BPRS-18 total scores of 18–31, N = 25), SZ-MO (BPRS-18 total scores of 32–41, N = 31), and SZ-PO (BPRS-18 total scores of ≥42, N = 23).
27-1	4383-4388	Based	_
27-2	4389-4391	on	_
27-3	4392-4397	these	_
27-4	4398-4406	criteria	_
27-5	4407-4408	,	_
27-6	4409-4411	we	_
27-7	4412-4422	classified	_
27-8	4423-4426	the	_
27-9	4427-4435	patients	_
27-10	4436-4440	into	_
27-11	4441-4442	3	_
27-12	4443-4449	groups	_
27-13	4450-4451	:	_
27-14	4452-4457	SZ-GO	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask
27-15	4458-4459	(	_
27-16	4460-4467	BPRS-18	_
27-17	4468-4473	total	_
27-18	4474-4480	scores	_
27-19	4481-4483	of	_
27-20	4484-4489	18–31	_
27-21	4490-4491	,	_
27-22	4492-4493	N	_
27-23	4494-4495	=	_
27-24	4496-4498	25	_
27-25	4499-4500	)	_
27-26	4501-4502	,	_
27-27	4503-4508	SZ-MO	http://maven.renci.org/NeuroBridge/neurobridge#Thing
27-28	4509-4510	(	_
27-29	4511-4518	BPRS-18	_
27-30	4519-4524	total	_
27-31	4525-4531	scores	_
27-32	4532-4534	of	_
27-33	4535-4540	32–41	_
27-34	4541-4542	,	_
27-35	4543-4544	N	_
27-36	4545-4546	=	_
27-37	4547-4549	31	_
27-38	4550-4551	)	_
27-39	4552-4553	,	_
27-40	4554-4557	and	_
27-41	4558-4563	SZ-PO	http://maven.renci.org/NeuroBridge/neurobridge#Thing
27-42	4564-4565	(	_
27-43	4566-4573	BPRS-18	_
27-44	4574-4579	total	_
27-45	4580-4586	scores	_
27-46	4587-4589	of	_
27-47	4590-4593	≥42	_
27-48	4594-4595	,	_
27-49	4596-4597	N	_
27-50	4598-4599	=	_
27-51	4600-4602	23	_
27-52	4603-4604	)	_
27-53	4605-4606	.	_

Text=In addition, according to the factor structure proposed by, the “ affect, ” “ positive symptoms, ” “ negative symptoms, ” “ resistance, ” and “ activation ” subscales of the BPRS-18 were analyzed as continuous variables.
28-1	4607-4609	In	_
28-2	4610-4618	addition	_
28-3	4619-4620	,	_
28-4	4621-4630	according	_
28-5	4631-4633	to	_
28-6	4634-4637	the	_
28-7	4638-4644	factor	_
28-8	4645-4654	structure	_
28-9	4655-4663	proposed	_
28-10	4664-4666	by	_
28-11	4667-4668	,	_
28-12	4669-4672	the	_
28-13	4673-4674	“	_
28-14	4675-4681	affect	_
28-15	4682-4683	,	_
28-16	4684-4685	”	_
28-17	4686-4687	“	_
28-18	4688-4696	positive	_
28-19	4697-4705	symptoms	_
28-20	4706-4707	,	_
28-21	4708-4709	”	_
28-22	4710-4711	“	_
28-23	4712-4720	negative	_
28-24	4721-4729	symptoms	_
28-25	4730-4731	,	_
28-26	4732-4733	”	_
28-27	4734-4735	“	_
28-28	4736-4746	resistance	_
28-29	4747-4748	,	_
28-30	4749-4750	”	_
28-31	4751-4754	and	_
28-32	4755-4756	“	_
28-33	4757-4767	activation	_
28-34	4768-4769	”	_
28-35	4770-4779	subscales	_
28-36	4780-4782	of	_
28-37	4783-4786	the	_
28-38	4787-4794	BPRS-18	_
28-39	4795-4799	were	_
28-40	4800-4808	analyzed	_
28-41	4809-4811	as	_
28-42	4812-4822	continuous	_
28-43	4823-4832	variables	_
28-44	4833-4834	.	_

Text=We also assessed the overall level of the patient's functioning using the WHO Disability Assessment Schedule 2.0 (WHODAS 2.0).
29-1	4835-4837	We	_
29-2	4838-4842	also	_
29-3	4843-4851	assessed	_
29-4	4852-4855	the	_
29-5	4856-4863	overall	_
29-6	4864-4869	level	_
29-7	4870-4872	of	_
29-8	4873-4876	the	_
29-9	4877-4884	patient	_
29-10	4885-4887	's	_
29-11	4888-4899	functioning	_
29-12	4900-4905	using	_
29-13	4906-4909	the	_
29-14	4910-4913	WHO	_
29-15	4914-4924	Disability	_
29-16	4925-4935	Assessment	_
29-17	4936-4944	Schedule	_
29-18	4945-4948	2.0	_
29-19	4949-4950	(	_
29-20	4951-4957	WHODAS	_
29-21	4958-4961	2.0	_
29-22	4962-4963	)	_
29-23	4964-4965	.	_

Text=Considering that functional outcomes of patients with schizophrenia correlate with their clinical outcomes, we compared the WHODAS 2.0 total score among SZ-GO, SZ-MO, and SZ-PO groups to confirm whether the grouping was appropriate.
30-1	4966-4977	Considering	_
30-2	4978-4982	that	_
30-3	4983-4993	functional	_
30-4	4994-5002	outcomes	_
30-5	5003-5005	of	_
30-6	5006-5014	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
30-7	5015-5019	with	_
30-8	5020-5033	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
30-9	5034-5043	correlate	_
30-10	5044-5048	with	_
30-11	5049-5054	their	_
30-12	5055-5063	clinical	_
30-13	5064-5072	outcomes	_
30-14	5073-5074	,	_
30-15	5075-5077	we	_
30-16	5078-5086	compared	_
30-17	5087-5090	the	_
30-18	5091-5097	WHODAS	_
30-19	5098-5101	2.0	_
30-20	5102-5107	total	_
30-21	5108-5113	score	_
30-22	5114-5119	among	_
30-23	5120-5125	SZ-GO	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask
30-24	5126-5127	,	_
30-25	5128-5133	SZ-MO	http://maven.renci.org/NeuroBridge/neurobridge#Thing
30-26	5134-5135	,	_
30-27	5136-5139	and	_
30-28	5140-5145	SZ-PO	http://maven.renci.org/NeuroBridge/neurobridge#Thing
30-29	5146-5152	groups	_
30-30	5153-5155	to	_
30-31	5156-5163	confirm	_
30-32	5164-5171	whether	_
30-33	5172-5175	the	_
30-34	5176-5184	grouping	_
30-35	5185-5188	was	_
30-36	5189-5200	appropriate	_
30-37	5201-5202	.	_

Text=MRI acquisition The MRI data were acquired using a 3-T MR scanner (Ingenia CX; Philips, Erlangen) equipped with a 32-channel head coil.
31-1	5203-5206	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
31-2	5207-5218	acquisition	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
31-3	5219-5222	The	_
31-4	5223-5226	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
31-5	5227-5231	data	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
31-6	5232-5236	were	_
31-7	5237-5245	acquired	_
31-8	5246-5251	using	_
31-9	5252-5253	a	_
31-10	5254-5257	3-T	http://maven.renci.org/NeuroBridge/neurobridge#2Level
31-11	5258-5260	MR	http://maven.renci.org/NeuroBridge/neurobridge#2Level
31-12	5261-5268	scanner	http://maven.renci.org/NeuroBridge/neurobridge#2Level
31-13	5269-5270	(	_
31-14	5271-5278	Ingenia	_
31-15	5279-5281	CX	_
31-16	5282-5283	;	_
31-17	5284-5291	Philips	_
31-18	5292-5293	,	_
31-19	5294-5302	Erlangen	_
31-20	5303-5304	)	_
31-21	5305-5313	equipped	_
31-22	5314-5318	with	_
31-23	5319-5320	a	_
31-24	5321-5331	32-channel	_
31-25	5332-5336	head	_
31-26	5337-5341	coil	_
31-27	5342-5343	.	_

Text=Blood oxygen-level dependent (BOLD) signals were obtained using a T2 * -weighted gradient echo planar imaging (EPI) sequence (TR = 2000 ms, TE = 30 ms, matrix size: 64 × 64, 45 interleaved slices, field of view = 220 mm, slice thickness = 3.5 mm, flip angle = 90°) parallel to the anterior commissure-posterior commissure line.
32-1	5344-5349	Blood	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
32-2	5350-5362	oxygen-level	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
32-3	5363-5372	dependent	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
32-4	5373-5374	(	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
32-5	5375-5379	BOLD	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
32-6	5380-5381	)	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
32-7	5382-5389	signals	http://maven.renci.org/NeuroBridge/neurobridge#BloodOxygenLevel
32-8	5390-5394	were	_
32-9	5395-5403	obtained	_
32-10	5404-5409	using	_
32-11	5410-5411	a	_
32-12	5412-5414	T2	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
32-13	5415-5416	*	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
32-14	5417-5426	-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
32-15	5427-5435	gradient	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
32-16	5436-5440	echo	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
32-17	5441-5447	planar	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
32-18	5448-5455	imaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
32-19	5456-5457	(	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
32-20	5458-5461	EPI	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
32-21	5462-5463	)	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
32-22	5464-5472	sequence	_
32-23	5473-5474	(	_
32-24	5475-5477	TR	_
32-25	5478-5479	=	_
32-26	5480-5484	2000	_
32-27	5485-5487	ms	_
32-28	5488-5489	,	_
32-29	5490-5492	TE	_
32-30	5493-5494	=	_
32-31	5495-5497	30	_
32-32	5498-5500	ms	_
32-33	5501-5502	,	_
32-34	5503-5509	matrix	_
32-35	5510-5514	size	_
32-36	5515-5516	:	_
32-37	5517-5519	64	_
32-38	5520-5521	×	_
32-39	5522-5524	64	_
32-40	5525-5526	,	_
32-41	5527-5529	45	_
32-42	5530-5541	interleaved	_
32-43	5542-5548	slices	_
32-44	5549-5550	,	_
32-45	5551-5556	field	_
32-46	5557-5559	of	_
32-47	5560-5564	view	_
32-48	5565-5566	=	_
32-49	5567-5570	220	_
32-50	5571-5573	mm	_
32-51	5574-5575	,	_
32-52	5576-5581	slice	_
32-53	5582-5591	thickness	_
32-54	5592-5593	=	_
32-55	5594-5597	3.5	_
32-56	5598-5600	mm	_
32-57	5601-5602	,	_
32-58	5603-5607	flip	_
32-59	5608-5613	angle	_
32-60	5614-5615	=	_
32-61	5616-5619	90°	_
32-62	5620-5621	)	_
32-63	5622-5630	parallel	_
32-64	5631-5633	to	_
32-65	5634-5637	the	_
32-66	5638-5646	anterior	_
32-67	5647-5667	commissure-posterior	_
32-68	5668-5678	commissure	_
32-69	5679-5683	line	_
32-70	5684-5685	.	_

Text=All subjects received a 5-min scan (150 volumes) during functional imaging plus two initial dummy volumes, which were acquired to ensure magnetization stabilization.
33-1	5686-5689	All	_
33-2	5690-5698	subjects	_
33-3	5699-5707	received	_
33-4	5708-5709	a	_
33-5	5710-5715	5-min	_
33-6	5716-5720	scan	_
33-7	5721-5722	(	_
33-8	5723-5726	150	_
33-9	5727-5734	volumes	_
33-10	5735-5736	)	_
33-11	5737-5743	during	_
33-12	5744-5754	functional	_
33-13	5755-5762	imaging	_
33-14	5763-5767	plus	_
33-15	5768-5771	two	_
33-16	5772-5779	initial	_
33-17	5780-5785	dummy	_
33-18	5786-5793	volumes	_
33-19	5794-5795	,	_
33-20	5796-5801	which	_
33-21	5802-5806	were	_
33-22	5807-5815	acquired	_
33-23	5816-5818	to	_
33-24	5819-5825	ensure	_
33-25	5826-5839	magnetization	_
33-26	5840-5853	stabilization	_
33-27	5854-5855	.	_

Text=During the functional scans, the participants were explicitly instructed to open their eyes and fixate on a white cross presented in the center of visual field.
34-1	5856-5862	During	_
34-2	5863-5866	the	_
34-3	5867-5877	functional	_
34-4	5878-5883	scans	_
34-5	5884-5885	,	_
34-6	5886-5889	the	_
34-7	5890-5902	participants	_
34-8	5903-5907	were	_
34-9	5908-5918	explicitly	_
34-10	5919-5929	instructed	_
34-11	5930-5932	to	_
34-12	5933-5937	open	_
34-13	5938-5943	their	_
34-14	5944-5948	eyes	_
34-15	5949-5952	and	_
34-16	5953-5959	fixate	_
34-17	5960-5962	on	_
34-18	5963-5964	a	_
34-19	5965-5970	white	_
34-20	5971-5976	cross	_
34-21	5977-5986	presented	_
34-22	5987-5989	in	_
34-23	5990-5993	the	_
34-24	5994-6000	center	_
34-25	6001-6003	of	_
34-26	6004-6010	visual	_
34-27	6011-6016	field	_
34-28	6017-6018	.	_

Text=A high-resolution anatomical T1 weighted image was also acquired using a turbo field echo sequence (spin-echo TR = 9.8 ms, TE = 4.6 ms, matrix size: 240 × 240, 170 sagittal slices, FOV = 240 mm, slice thickness = 1 mm, flip angle = 8°).
35-1	6019-6020	A	_
35-2	6021-6036	high-resolution	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
35-3	6037-6047	anatomical	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
35-4	6048-6050	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
35-5	6051-6059	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
35-6	6060-6065	image	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
35-7	6066-6069	was	_
35-8	6070-6074	also	_
35-9	6075-6083	acquired	_
35-10	6084-6089	using	_
35-11	6090-6091	a	_
35-12	6092-6097	turbo	_
35-13	6098-6103	field	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
35-14	6104-6108	echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
35-15	6109-6117	sequence	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
35-16	6118-6119	(	_
35-17	6120-6129	spin-echo	http://maven.renci.org/NeuroBridge/neurobridge#Spectroscopy
35-18	6130-6132	TR	_
35-19	6133-6134	=	_
35-20	6135-6138	9.8	_
35-21	6139-6141	ms	_
35-22	6142-6143	,	_
35-23	6144-6146	TE	_
35-24	6147-6148	=	_
35-25	6149-6152	4.6	_
35-26	6153-6155	ms	_
35-27	6156-6157	,	_
35-28	6158-6164	matrix	_
35-29	6165-6169	size	_
35-30	6170-6171	:	_
35-31	6172-6175	240	_
35-32	6176-6177	×	_
35-33	6178-6181	240	_
35-34	6182-6183	,	_
35-35	6184-6187	170	_
35-36	6188-6196	sagittal	_
35-37	6197-6203	slices	_
35-38	6204-6205	,	_
35-39	6206-6209	FOV	_
35-40	6210-6211	=	_
35-41	6212-6215	240	_
35-42	6216-6218	mm	_
35-43	6219-6220	,	_
35-44	6221-6226	slice	_
35-45	6227-6236	thickness	_
35-46	6237-6238	=	_
35-47	6239-6240	1	_
35-48	6241-6243	mm	_
35-49	6244-6245	,	_
35-50	6246-6250	flip	_
35-51	6251-6256	angle	_
35-52	6257-6258	=	_
35-53	6259-6261	8°	_
35-54	6262-6263	)	_
35-55	6264-6265	.	_

Text=Resting-state fMRI analysis The fMRI data analysis was performed using the Analysis of Functional NeuroImages (AFNI) software (version 18.2.04).
36-1	6266-6279	Resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
36-2	6280-6284	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
36-3	6285-6293	analysis	_
36-4	6294-6297	The	_
36-5	6298-6302	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
36-6	6303-6307	data	_
36-7	6308-6316	analysis	_
36-8	6317-6320	was	_
36-9	6321-6330	performed	_
36-10	6331-6336	using	_
36-11	6337-6340	the	_
36-12	6341-6349	Analysis	_
36-13	6350-6352	of	_
36-14	6353-6363	Functional	_
36-15	6364-6375	NeuroImages	_
36-16	6376-6377	(	_
36-17	6378-6382	AFNI	_
36-18	6383-6384	)	_
36-19	6385-6393	software	_
36-20	6394-6395	(	_
36-21	6396-6403	version	_
36-22	6404-6411	18.2.04	_
36-23	6412-6413	)	_
36-24	6414-6415	.	_

Text=The first three volumes were discarded from the functional dataset to allow for signal stabilization.
37-1	6416-6419	The	_
37-2	6420-6425	first	_
37-3	6426-6431	three	_
37-4	6432-6439	volumes	_
37-5	6440-6444	were	_
37-6	6445-6454	discarded	_
37-7	6455-6459	from	_
37-8	6460-6463	the	_
37-9	6464-6474	functional	_
37-10	6475-6482	dataset	_
37-11	6483-6485	to	_
37-12	6486-6491	allow	_
37-13	6492-6495	for	_
37-14	6496-6502	signal	_
37-15	6503-6516	stabilization	_
37-16	6517-6518	.	_

Text=Despiking was performed for each voxel time-series to suppress local spikes in the EPI signals.
38-1	6519-6528	Despiking	_
38-2	6529-6532	was	_
38-3	6533-6542	performed	_
38-4	6543-6546	for	_
38-5	6547-6551	each	_
38-6	6552-6557	voxel	_
38-7	6558-6569	time-series	_
38-8	6570-6572	to	_
38-9	6573-6581	suppress	_
38-10	6582-6587	local	_
38-11	6588-6594	spikes	_
38-12	6595-6597	in	_
38-13	6598-6601	the	_
38-14	6602-6605	EPI	_
38-15	6606-6613	signals	_
38-16	6614-6615	.	_

Text=Head motion correction was conducted by rigid body registration of EPI volumes to a base EPI volume.
39-1	6616-6620	Head	_
39-2	6621-6627	motion	_
39-3	6628-6638	correction	_
39-4	6639-6642	was	_
39-5	6643-6652	conducted	_
39-6	6653-6655	by	_
39-7	6656-6661	rigid	_
39-8	6662-6666	body	_
39-9	6667-6679	registration	_
39-10	6680-6682	of	_
39-11	6683-6686	EPI	_
39-12	6687-6694	volumes	_
39-13	6695-6697	to	_
39-14	6698-6699	a	_
39-15	6700-6704	base	_
39-16	6705-6708	EPI	_
39-17	6709-6715	volume	_
39-18	6716-6717	.	_

Text=Physiological respiratory and cardiac artifacts were estimated and corrected using Physiologic EStimation by Temporal ICA (PESTICA).
40-1	6718-6731	Physiological	_
40-2	6732-6743	respiratory	_
40-3	6744-6747	and	_
40-4	6748-6755	cardiac	_
40-5	6756-6765	artifacts	_
40-6	6766-6770	were	_
40-7	6771-6780	estimated	_
40-8	6781-6784	and	_
40-9	6785-6794	corrected	_
40-10	6795-6800	using	_
40-11	6801-6812	Physiologic	_
40-12	6813-6823	EStimation	_
40-13	6824-6826	by	_
40-14	6827-6835	Temporal	_
40-15	6836-6839	ICA	_
40-16	6840-6841	(	_
40-17	6842-6849	PESTICA	_
40-18	6850-6851	)	_
40-19	6852-6853	.	_

Text=Slice-timing correction was carried out for all slices within a volume.
41-1	6854-6866	Slice-timing	_
41-2	6867-6877	correction	_
41-3	6878-6881	was	_
41-4	6882-6889	carried	_
41-5	6890-6893	out	_
41-6	6894-6897	for	_
41-7	6898-6901	all	_
41-8	6902-6908	slices	_
41-9	6909-6915	within	_
41-10	6916-6917	a	_
41-11	6918-6924	volume	_
41-12	6925-6926	.	_

Text=After co-registration to high-resolution anatomical T1 images, spatial normalization was performed by affine transform, using the parameters obtained from spatial normalization of the T1 images into Montreal Neurological Institute (MNI) stereotactic space with the MNI avg152T1 template.
42-1	6927-6932	After	_
42-2	6933-6948	co-registration	_
42-3	6949-6951	to	_
42-4	6952-6967	high-resolution	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
42-5	6968-6978	anatomical	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
42-6	6979-6981	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
42-7	6982-6988	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
42-8	6989-6990	,	_
42-9	6991-6998	spatial	_
42-10	6999-7012	normalization	_
42-11	7013-7016	was	_
42-12	7017-7026	performed	_
42-13	7027-7029	by	_
42-14	7030-7036	affine	_
42-15	7037-7046	transform	_
42-16	7047-7048	,	_
42-17	7049-7054	using	_
42-18	7055-7058	the	_
42-19	7059-7069	parameters	_
42-20	7070-7078	obtained	_
42-21	7079-7083	from	_
42-22	7084-7091	spatial	_
42-23	7092-7105	normalization	_
42-24	7106-7108	of	_
42-25	7109-7112	the	_
42-26	7113-7115	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
42-27	7116-7122	images	_
42-28	7123-7127	into	_
42-29	7128-7136	Montreal	_
42-30	7137-7149	Neurological	_
42-31	7150-7159	Institute	_
42-32	7160-7161	(	_
42-33	7162-7165	MNI	_
42-34	7166-7167	)	_
42-35	7168-7180	stereotactic	_
42-36	7181-7186	space	_
42-37	7187-7191	with	_
42-38	7192-7195	the	_
42-39	7196-7199	MNI	_
42-40	7200-7208	avg152T1	_
42-41	7209-7217	template	_
42-42	7218-7219	.	_

Text=All voxels were resampled to 2 × 2 × 2 mm by nearest neighbor interpolation.
43-1	7220-7223	All	_
43-2	7224-7230	voxels	_
43-3	7231-7235	were	_
43-4	7236-7245	resampled	_
43-5	7246-7248	to	_
43-6	7249-7250	2	_
43-7	7251-7252	×	_
43-8	7253-7254	2	_
43-9	7255-7256	×	_
43-10	7257-7258	2	_
43-11	7259-7261	mm	_
43-12	7262-7264	by	_
43-13	7265-7272	nearest	_
43-14	7273-7281	neighbor	_
43-15	7282-7295	interpolation	_
43-16	7296-7297	.	_

Text=A temporal band-pass filter was applied at 0.009 Hz <f <0.08 Hz.
44-1	7298-7299	A	_
44-2	7300-7308	temporal	_
44-3	7309-7318	band-pass	_
44-4	7319-7325	filter	_
44-5	7326-7329	was	_
44-6	7330-7337	applied	_
44-7	7338-7340	at	_
44-8	7341-7346	0.009	_
44-9	7347-7349	Hz	_
44-10	7350-7351	<	_
44-11	7352-7353	f	_
44-12	7354-7355	<	_
44-13	7356-7360	0.08	_
44-14	7361-7363	Hz	_
44-15	7364-7365	.	_

Text=The nuisance signals, which consisted of six parameters obtained by correction of head motion and non-neural sources of variance from the eroded white matter and the eroded large ventricle mask, were regressed out.
45-1	7366-7369	The	_
45-2	7370-7378	nuisance	_
45-3	7379-7386	signals	_
45-4	7387-7388	,	_
45-5	7389-7394	which	_
45-6	7395-7404	consisted	_
45-7	7405-7407	of	_
45-8	7408-7411	six	_
45-9	7412-7422	parameters	_
45-10	7423-7431	obtained	_
45-11	7432-7434	by	_
45-12	7435-7445	correction	_
45-13	7446-7448	of	_
45-14	7449-7453	head	_
45-15	7454-7460	motion	_
45-16	7461-7464	and	_
45-17	7465-7475	non-neural	_
45-18	7476-7483	sources	_
45-19	7484-7486	of	_
45-20	7487-7495	variance	_
45-21	7496-7500	from	_
45-22	7501-7504	the	_
45-23	7505-7511	eroded	_
45-24	7512-7517	white	_
45-25	7518-7524	matter	_
45-26	7525-7528	and	_
45-27	7529-7532	the	_
45-28	7533-7539	eroded	_
45-29	7540-7545	large	_
45-30	7546-7555	ventricle	_
45-31	7556-7560	mask	_
45-32	7561-7562	,	_
45-33	7563-7567	were	_
45-34	7568-7577	regressed	_
45-35	7578-7581	out	_
45-36	7582-7583	.	_

Text=Additionally, outlier volumes were censored from the time-series based on a threshold of framewise displacement, which was taken as the sum of the absolute value of temporal differences across the six motion parameters.
46-1	7584-7596	Additionally	_
46-2	7597-7598	,	_
46-3	7599-7606	outlier	_
46-4	7607-7614	volumes	_
46-5	7615-7619	were	_
46-6	7620-7628	censored	_
46-7	7629-7633	from	_
46-8	7634-7637	the	_
46-9	7638-7649	time-series	_
46-10	7650-7655	based	_
46-11	7656-7658	on	_
46-12	7659-7660	a	_
46-13	7661-7670	threshold	_
46-14	7671-7673	of	_
46-15	7674-7683	framewise	_
46-16	7684-7696	displacement	_
46-17	7697-7698	,	_
46-18	7699-7704	which	_
46-19	7705-7708	was	_
46-20	7709-7714	taken	_
46-21	7715-7717	as	_
46-22	7718-7721	the	_
46-23	7722-7725	sum	_
46-24	7726-7728	of	_
46-25	7729-7732	the	_
46-26	7733-7741	absolute	_
46-27	7742-7747	value	_
46-28	7748-7750	of	_
46-29	7751-7759	temporal	_
46-30	7760-7771	differences	_
46-31	7772-7778	across	_
46-32	7779-7782	the	_
46-33	7783-7786	six	_
46-34	7787-7793	motion	_
46-35	7794-7804	parameters	_
46-36	7805-7806	.	_

Text=The time-points with a framewise displacement that exceeded 0.5 mm, also including the one preceding and following time-points, were excluded.
47-1	7807-7810	The	_
47-2	7811-7822	time-points	_
47-3	7823-7827	with	_
47-4	7828-7829	a	_
47-5	7830-7839	framewise	_
47-6	7840-7852	displacement	_
47-7	7853-7857	that	_
47-8	7858-7866	exceeded	_
47-9	7867-7870	0.5	_
47-10	7871-7873	mm	_
47-11	7874-7875	,	_
47-12	7876-7880	also	_
47-13	7881-7890	including	_
47-14	7891-7894	the	_
47-15	7895-7898	one	_
47-16	7899-7908	preceding	_
47-17	7909-7912	and	_
47-18	7913-7922	following	_
47-19	7923-7934	time-points	_
47-20	7935-7936	,	_
47-21	7937-7941	were	_
47-22	7942-7950	excluded	_
47-23	7951-7952	.	_

Text=Spatial smoothing was conducted with an isotropic Gaussian kernel of 7 mm full width at half-maximum.
48-1	7953-7960	Spatial	_
48-2	7961-7970	smoothing	_
48-3	7971-7974	was	_
48-4	7975-7984	conducted	_
48-5	7985-7989	with	_
48-6	7990-7992	an	_
48-7	7993-8002	isotropic	_
48-8	8003-8011	Gaussian	_
48-9	8012-8018	kernel	_
48-10	8019-8021	of	_
48-11	8022-8023	7	_
48-12	8024-8026	mm	_
48-13	8027-8031	full	_
48-14	8032-8037	width	_
48-15	8038-8040	at	_
48-16	8041-8053	half-maximum	_
48-17	8054-8055	.	_

Text=In order to identify the default mode network, we performed seed-based functional connectivity analysis using the bilateral PCC (MNI coordinate x = ±6, y = 54, z = 26, radius = 6 mm).
49-1	8056-8058	In	_
49-2	8059-8064	order	_
49-3	8065-8067	to	_
49-4	8068-8076	identify	_
49-5	8077-8080	the	_
49-6	8081-8088	default	_
49-7	8089-8093	mode	_
49-8	8094-8101	network	_
49-9	8102-8103	,	_
49-10	8104-8106	we	_
49-11	8107-8116	performed	_
49-12	8117-8127	seed-based	_
49-13	8128-8138	functional	_
49-14	8139-8151	connectivity	_
49-15	8152-8160	analysis	_
49-16	8161-8166	using	_
49-17	8167-8170	the	_
49-18	8171-8180	bilateral	_
49-19	8181-8184	PCC	_
49-20	8185-8186	(	_
49-21	8187-8190	MNI	_
49-22	8191-8201	coordinate	_
49-23	8202-8203	x	_
49-24	8204-8205	=	_
49-25	8206-8208	±6	_
49-26	8209-8210	,	_
49-27	8211-8212	y	_
49-28	8213-8214	=	_
49-29	8215-8217	54	_
49-30	8218-8219	,	_
49-31	8220-8221	z	_
49-32	8222-8223	=	_
49-33	8224-8226	26	_
49-34	8227-8228	,	_
49-35	8229-8235	radius	_
49-36	8236-8237	=	_
49-37	8238-8239	6	_
49-38	8240-8242	mm	_
49-39	8243-8244	)	_
49-40	8245-8246	.	_

Text=Individual functional connectivity maps were produced by correlation analysis between the average time course in the seed region and the time courses from the whole brain.
50-1	8247-8257	Individual	_
50-2	8258-8268	functional	_
50-3	8269-8281	connectivity	_
50-4	8282-8286	maps	_
50-5	8287-8291	were	_
50-6	8292-8300	produced	_
50-7	8301-8303	by	_
50-8	8304-8315	correlation	_
50-9	8316-8324	analysis	_
50-10	8325-8332	between	_
50-11	8333-8336	the	_
50-12	8337-8344	average	_
50-13	8345-8349	time	_
50-14	8350-8356	course	_
50-15	8357-8359	in	_
50-16	8360-8363	the	_
50-17	8364-8368	seed	_
50-18	8369-8375	region	_
50-19	8376-8379	and	_
50-20	8380-8383	the	_
50-21	8384-8388	time	_
50-22	8389-8396	courses	_
50-23	8397-8401	from	_
50-24	8402-8405	the	_
50-25	8406-8411	whole	_
50-26	8412-8417	brain	_
50-27	8418-8419	.	_

Text=The correlation coefficients were converted into z-values as functional connectivity strengths, using Fisher's r-to-z transformation.
51-1	8420-8423	The	_
51-2	8424-8435	correlation	_
51-3	8436-8448	coefficients	_
51-4	8449-8453	were	_
51-5	8454-8463	converted	_
51-6	8464-8468	into	_
51-7	8469-8477	z-values	_
51-8	8478-8480	as	_
51-9	8481-8491	functional	_
51-10	8492-8504	connectivity	_
51-11	8505-8514	strengths	_
51-12	8515-8516	,	_
51-13	8517-8522	using	_
51-14	8523-8529	Fisher	_
51-15	8530-8532	's	_
51-16	8533-8539	r-to-z	_
51-17	8540-8554	transformation	_
51-18	8555-8556	.	_

Text=Statistical analyses To identify within-group functional connectivity patterns, a one-sample t-test was performed.
52-1	8557-8568	Statistical	_
52-2	8569-8577	analyses	_
52-3	8578-8580	To	_
52-4	8581-8589	identify	_
52-5	8590-8602	within-group	_
52-6	8603-8613	functional	_
52-7	8614-8626	connectivity	_
52-8	8627-8635	patterns	_
52-9	8636-8637	,	_
52-10	8638-8639	a	_
52-11	8640-8650	one-sample	_
52-12	8651-8657	t-test	_
52-13	8658-8661	was	_
52-14	8662-8671	performed	_
52-15	8672-8673	.	_

Text=Then, we explored brain regions showing differences in DMN connectivity among the HC and 3 schizophrenia outcome groups using analysis of covariance (ANCOVA), adjusting for sex, age, and education in the AFNI software.
53-1	8674-8678	Then	_
53-2	8679-8680	,	_
53-3	8681-8683	we	_
53-4	8684-8692	explored	_
53-5	8693-8698	brain	_
53-6	8699-8706	regions	_
53-7	8707-8714	showing	_
53-8	8715-8726	differences	_
53-9	8727-8729	in	_
53-10	8730-8733	DMN	_
53-11	8734-8746	connectivity	_
53-12	8747-8752	among	_
53-13	8753-8756	the	_
53-14	8757-8759	HC	_
53-15	8760-8763	and	_
53-16	8764-8765	3	_
53-17	8766-8779	schizophrenia	_
53-18	8780-8787	outcome	_
53-19	8788-8794	groups	_
53-20	8795-8800	using	_
53-21	8801-8809	analysis	_
53-22	8810-8812	of	_
53-23	8813-8823	covariance	_
53-24	8824-8825	(	_
53-25	8826-8832	ANCOVA	_
53-26	8833-8834	)	_
53-27	8835-8836	,	_
53-28	8837-8846	adjusting	_
53-29	8847-8850	for	_
53-30	8851-8854	sex	_
53-31	8855-8856	,	_
53-32	8857-8860	age	_
53-33	8861-8862	,	_
53-34	8863-8866	and	_
53-35	8867-8876	education	_
53-36	8877-8879	in	_
53-37	8880-8883	the	_
53-38	8884-8888	AFNI	_
53-39	8889-8897	software	_
53-40	8898-8899	.	_

Text=Significance thresholding for group analysis was determined using 3dClustSim, as available in the AFNI software suite.
54-1	8900-8912	Significance	_
54-2	8913-8925	thresholding	_
54-3	8926-8929	for	_
54-4	8930-8935	group	_
54-5	8936-8944	analysis	_
54-6	8945-8948	was	_
54-7	8949-8959	determined	_
54-8	8960-8965	using	_
54-9	8966-8976	3dClustSim	_
54-10	8977-8978	,	_
54-11	8979-8981	as	_
54-12	8982-8991	available	_
54-13	8992-8994	in	_
54-14	8995-8998	the	_
54-15	8999-9003	AFNI	_
54-16	9004-9012	software	_
54-17	9013-9018	suite	_
54-18	9019-9020	.	_

Text=We adopted a voxel-wise threshold of P <.001 within a cluster extent threshold of 114 voxels, which corresponded to a family-wise error corrected P <.01.
55-1	9021-9023	We	_
55-2	9024-9031	adopted	_
55-3	9032-9033	a	_
55-4	9034-9044	voxel-wise	_
55-5	9045-9054	threshold	_
55-6	9055-9057	of	_
55-7	9058-9059	P	_
55-8	9060-9061	<	_
55-9	9062-9066	.001	_
55-10	9067-9073	within	_
55-11	9074-9075	a	_
55-12	9076-9083	cluster	_
55-13	9084-9090	extent	_
55-14	9091-9100	threshold	_
55-15	9101-9103	of	_
55-16	9104-9107	114	_
55-17	9108-9114	voxels	_
55-18	9115-9116	,	_
55-19	9117-9122	which	_
55-20	9123-9135	corresponded	_
55-21	9136-9138	to	_
55-22	9139-9140	a	_
55-23	9141-9152	family-wise	_
55-24	9153-9158	error	_
55-25	9159-9168	corrected	_
55-26	9169-9170	P	_
55-27	9171-9172	<	_
55-28	9173-9176	.01	_
55-29	9177-9178	.	_

Text=In the regions showing significant differences among the 4 groups, we extracted mean values of functional connectivity strength.
56-1	9179-9181	In	_
56-2	9182-9185	the	_
56-3	9186-9193	regions	_
56-4	9194-9201	showing	_
56-5	9202-9213	significant	_
56-6	9214-9225	differences	_
56-7	9226-9231	among	_
56-8	9232-9235	the	_
56-9	9236-9237	4	_
56-10	9238-9244	groups	_
56-11	9245-9246	,	_
56-12	9247-9249	we	_
56-13	9250-9259	extracted	_
56-14	9260-9264	mean	_
56-15	9265-9271	values	_
56-16	9272-9274	of	_
56-17	9275-9285	functional	_
56-18	9286-9298	connectivity	_
56-19	9299-9307	strength	_
56-20	9308-9309	.	_

Text=Then, we examined differences in DMN connectivity between pairs of groups using Bonferroni post-hoc test after ANCOVA adjusting for sex, age, and education, using the Statistical Package for the Social Science (SPSS) version 21.0 (IBM Corp., Armonk, NY, USA).
57-1	9310-9314	Then	_
57-2	9315-9316	,	_
57-3	9317-9319	we	_
57-4	9320-9328	examined	_
57-5	9329-9340	differences	_
57-6	9341-9343	in	_
57-7	9344-9347	DMN	_
57-8	9348-9360	connectivity	_
57-9	9361-9368	between	_
57-10	9369-9374	pairs	_
57-11	9375-9377	of	_
57-12	9378-9384	groups	_
57-13	9385-9390	using	_
57-14	9391-9401	Bonferroni	_
57-15	9402-9410	post-hoc	_
57-16	9411-9415	test	_
57-17	9416-9421	after	_
57-18	9422-9428	ANCOVA	_
57-19	9429-9438	adjusting	_
57-20	9439-9442	for	_
57-21	9443-9446	sex	_
57-22	9447-9448	,	_
57-23	9449-9452	age	_
57-24	9453-9454	,	_
57-25	9455-9458	and	_
57-26	9459-9468	education	_
57-27	9469-9470	,	_
57-28	9471-9476	using	_
57-29	9477-9480	the	_
57-30	9481-9492	Statistical	_
57-31	9493-9500	Package	_
57-32	9501-9504	for	_
57-33	9505-9508	the	_
57-34	9509-9515	Social	_
57-35	9516-9523	Science	_
57-36	9524-9525	(	_
57-37	9526-9530	SPSS	_
57-38	9531-9532	)	_
57-39	9533-9540	version	_
57-40	9541-9545	21.0	_
57-41	9546-9547	(	_
57-42	9548-9551	IBM	_
57-43	9552-9557	Corp.	_
57-44	9558-9559	,	_
57-45	9560-9566	Armonk	_
57-46	9567-9568	,	_
57-47	9569-9571	NY	_
57-48	9572-9573	,	_
57-49	9574-9577	USA	_
57-50	9578-9579	)	_
57-51	9580-9581	.	_

Text=In addition, we performed partial correlation analyses between mean values of DMN connectivity and BPRS-18 subscale scores, adjusting for sex, age, education, and chlorpromazine equivalent dose of antipsychotic drug (only in patients with schizophrenia).
58-1	9582-9584	In	_
58-2	9585-9593	addition	_
58-3	9594-9595	,	_
58-4	9596-9598	we	_
58-5	9599-9608	performed	_
58-6	9609-9616	partial	_
58-7	9617-9628	correlation	_
58-8	9629-9637	analyses	_
58-9	9638-9645	between	_
58-10	9646-9650	mean	_
58-11	9651-9657	values	_
58-12	9658-9660	of	_
58-13	9661-9664	DMN	_
58-14	9665-9677	connectivity	_
58-15	9678-9681	and	_
58-16	9682-9689	BPRS-18	_
58-17	9690-9698	subscale	_
58-18	9699-9705	scores	_
58-19	9706-9707	,	_
58-20	9708-9717	adjusting	_
58-21	9718-9721	for	_
58-22	9722-9725	sex	_
58-23	9726-9727	,	_
58-24	9728-9731	age	_
58-25	9732-9733	,	_
58-26	9734-9743	education	_
58-27	9744-9745	,	_
58-28	9746-9749	and	_
58-29	9750-9764	chlorpromazine	_
58-30	9765-9775	equivalent	_
58-31	9776-9780	dose	_
58-32	9781-9783	of	_
58-33	9784-9797	antipsychotic	_
58-34	9798-9802	drug	_
58-35	9803-9804	(	_
58-36	9805-9809	only	_
58-37	9810-9812	in	_
58-38	9813-9821	patients	_
58-39	9822-9826	with	_
58-40	9827-9840	schizophrenia	_
58-41	9841-9842	)	_
58-42	9843-9844	.	_

Text=The partial correlation analyses were also performed using SPSS.
59-1	9845-9848	The	_
59-2	9849-9856	partial	_
59-3	9857-9868	correlation	_
59-4	9869-9877	analyses	_
59-5	9878-9882	were	_
59-6	9883-9887	also	_
59-7	9888-9897	performed	_
59-8	9898-9903	using	_
59-9	9904-9908	SPSS	_
59-10	9909-9910	.	_

Text=For the post-hoc tests and partial correlation analyses, P <.05 was considered statistically significant.
60-1	9911-9914	For	_
60-2	9915-9918	the	_
60-3	9919-9927	post-hoc	_
60-4	9928-9933	tests	_
60-5	9934-9937	and	_
60-6	9938-9945	partial	_
60-7	9946-9957	correlation	_
60-8	9958-9966	analyses	_
60-9	9967-9968	,	_
60-10	9969-9970	P	_
60-11	9971-9972	<	_
60-12	9973-9976	.05	_
60-13	9977-9980	was	_
60-14	9981-9991	considered	_
60-15	9992-10005	statistically	_
60-16	10006-10017	significant	_
60-17	10018-10019	.	_

